Published in Oncotarget on April 04, 2017
Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance. Front Immunol (2017) 0.75
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 12.75
In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today (1990) 10.84
Multiple myeloma. N Engl J Med (2011) 10.38
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia (2008) 8.85
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 8.77
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med (2013) 6.21
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 4.76
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 4.37
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol (2014) 4.37
The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood (2009) 3.56
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23
Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J (2003) 3.06
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia (2009) 2.50
Treatment of multiple myeloma. Nat Rev Clin Oncol (2011) 2.46
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 2.41
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest (2013) 2.34
Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med (2014) 2.33
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol (2005) 1.99
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood (2004) 1.95
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother (2008) 1.95
Pathogenesis of myeloma. Annu Rev Pathol (2011) 1.91
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia (2007) 1.86
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol (2010) 1.76
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res (2007) 1.70
Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma (2011) 1.70
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood (2010) 1.66
Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma (2009) 1.63
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood (2013) 1.61
Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets (2010) 1.60
IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res (2011) 1.59
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A (2008) 1.59
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med (2014) 1.59
Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol (2008) 1.57
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood (2013) 1.55
Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing. Blood (2015) 1.48
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother (2011) 1.47
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood (2011) 1.41
Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia (2006) 1.40
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia (2012) 1.39
Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci (2008) 1.24
Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood (2013) 1.22
Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant (2011) 1.19
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol (2016) 1.17
The NKG2D receptor: sensing stressed cells. Trends Mol Med (2008) 1.17
Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev (2015) 1.16
Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant. Curr Opin Hematol (2012) 1.15
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant (2009) 1.14
Lenalidomide mode of action: linking bench and clinical findings. Blood Rev (2010) 1.12
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol (2012) 1.12
Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother (2012) 1.10
Natural killer cell immune escape in acute myeloid leukemia. Leukemia (2012) 1.10
Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin Immunol (2007) 1.08
Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia (2013) 1.08
Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol (2013) 1.07
Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia (2006) 1.06
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity (2016) 1.06
Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clin Dev Immunol (2012) 1.03
The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma (2012) 1.02
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J (2013) 1.01
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res (2015) 1.00
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res (2015) 0.98
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. Exp Hematol (2012) 0.98
Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol (2007) 0.97
MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes. Cancer Res (2005) 0.95
How "immunomodulatory" are IMIDs? Blood (2011) 0.95
Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3. J Immunol (2013) 0.95
Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions. Transfusion (2012) 0.94
Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94
Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immunother (2009) 0.94
Myeloma today: Disease definitions and treatment advances. Am J Hematol (2016) 0.94
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J Clin Oncol (2015) 0.94
Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma (2013) 0.93
Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood (2015) 0.93
Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy. Immunology (2013) 0.91
Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy. Blood Rev (2014) 0.91
Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget (2015) 0.90
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia (2015) 0.90
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev (2008) 0.90
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. Clin Exp Immunol (2014) 0.89
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica (2014) 0.89
Novel immune modulators used in hematology: impact on NK cells. Front Immunol (2013) 0.89
Immune checkpoint blockade: Releasing the brake towards hematological malignancies. Blood Rev (2015) 0.89
Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma (2003) 0.88
Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation. Cancer Immunol Immunother (2014) 0.87
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia (2013) 0.87
PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy. PLoS One (2015) 0.86
Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Res Int (2014) 0.86
Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest (2015) 0.86
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta (2015) 0.86